In our exclusive interview, Aditya Bardia, MD, MPH, sheds light on the considerations that should be made leading up to treatment selection in common clinical scenarios in breast cancer.
Welcome to OncLive On Air™! I’m your host today, Caroline Seymour.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Aditya Bardia, MD, MPH, director of Precision Medicine at the Center for Breast Cancer and founding director of the Molecular and Precision Medicine Metastatic Breast Cancer Clinic, Massachusetts General Hospital Cancer Center, and assistant professor of medicine, Harvard Medical School, to bring clinical scenarios to light across breast cancer subtypes.
The availability of targeted therapy, antibody-drug conjugates, and immunotherapy necessitates greater discussions regarding second-line treatment for patients with metastatic hormone receptor–positive, HER2-negative breast cancer, third-line treatment for patients with metastatic HER2-positive breast cancer, and neoadjuvant therapy for patients with locally advanced triple-negative breast cancer.
In our exclusive interview, Bardia shed light on the considerations that should be made leading up to treatment selection in common clinical scenarios in breast cancer.